A Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety and Tolerability of SAF312 in Subjects With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions Who Are Inadequately Managed by Antimuscarinic Therapy
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2017
At a glance
- Drugs SAF 312 (Primary)
- Indications Neurogenic bladder; Overactive bladder
- Focus Therapeutic Use
- Sponsors Novartis
- 19 Mar 2013 Actual end date changed from Dec 2012 to Sep 2012, as reported by ClinicalTrials.gov.
- 01 Dec 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 May 2012 Additional location (Belgium) added as reported by European Clinical Trials Database.